RxSight, Inc.
RXST
$5.55
$0.030.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.89M | 32.61M | 30.34M | 33.64M | 37.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.89M | 32.61M | 30.34M | 33.64M | 37.90M |
| Cost of Revenue | 7.40M | 7.35M | 6.11M | 8.45M | 9.57M |
| Gross Profit | 23.50M | 25.26M | 24.23M | 25.19M | 28.33M |
| SG&A Expenses | 31.86M | 27.70M | 27.35M | 28.98M | 28.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.72M | 43.95M | 42.52M | 47.64M | 48.57M |
| Operating Income | -17.83M | -11.34M | -12.18M | -14.00M | -10.67M |
| Income Before Tax | -15.88M | -9.15M | -9.81M | -11.75M | -8.17M |
| Income Tax Expenses | 6.00K | 5.00K | 10.00K | 32.00K | 18.00K |
| Earnings from Continuing Operations | -15.88M | -9.15M | -9.82M | -11.79M | -8.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.88M | -9.15M | -9.82M | -11.79M | -8.19M |
| EBIT | -17.83M | -11.34M | -12.18M | -14.00M | -10.67M |
| EBITDA | -17.00M | -10.49M | -11.32M | -13.22M | -9.90M |
| EPS Basic | -0.38 | -0.22 | -0.24 | -0.29 | -0.20 |
| Normalized Basic EPS | -0.24 | -0.14 | -0.15 | -0.18 | -0.13 |
| EPS Diluted | -0.38 | -0.22 | -0.24 | -0.29 | -0.20 |
| Normalized Diluted EPS | -0.24 | -0.14 | -0.15 | -0.18 | -0.13 |
| Average Basic Shares Outstanding | 41.31M | 41.18M | 40.97M | 40.74M | 40.51M |
| Average Diluted Shares Outstanding | 41.31M | 41.18M | 40.97M | 40.74M | 40.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |